A pilot study in pts with metastatic colorectal cancer, treated with mitomycin C 15 mg/m 2 i.v. bolus day i and 5-fluorouracil 30 mg/kg/day continuously infused days 1-5 repeated every 6 weeks, showed partial responses in 6 of 15 patients (40 %). Plasmapheresis in 23 pts with chemotherapy-resistant colorectal cancer was able to overcome the drug resistance in 15 of 23 pts.
Here we report on a randomized prospective trial comparing the two treatment modalities. 16 pts were randomized into group A (CT with mitomycin C and 5-FU, dose as above) and 16 into group B (plasmapheresis and CT). The results are shown in In a recent phase II trial we have shown a favorable response rate for sequential MTX/FU in CRC (JCO 2: 591).Since 7/83 166 patients(pts) with measurable metastatic CRC have been proBpectively randomized to receive e~ther MTX/FU(MTX 15N mg/m-iv push followed by MTX 150 mg/m ~ iv infusion over 4 hrs, FU 900 mg/m~ 7 hrs after start of MTX and leucovorin 15 mg po q 6 hrs ~ 8 beginning 24 hrs after MTX) or FU alone(FU 450 mg/m iv push qdx5). MTX/FU was repeated q 2 weeks x3, then q 3 weeks. FU cycles were given q 3 weeks. Eligibility criteria included ECOG performance stetus(PS) 0-3, age < 76, creatinine clearance >70 ml/min, absence of major effusion, no prior chemotherapy. Survival was the primary study endpoint. The two groups are comparable with respect to age, PS, prior weight loss, localisation of the primary, histologic grade and disease-free interval. At the present time 126 pts are evaluable, 73 have been followed to time of death. Response rate for MTX/FU is 28% with 3 CRs and 14 PRs. For FU alone response rat~ is 15%(1 CR,9 PRs). This~difference indicates a trend in favor of MTX/FU (p=O.08, x~-test). Median duration of response was 8.2 mo(MTX/FU) and 7.5 mo (FU) resp. Curves of overall survival are almost identical with a median of 10.7 mo(MTX/FU) and 12.8 mo(FU) resp. Leukocytopenia and stomatitis were significantly more common in pts receiving PU alone, while other side effects were usually mild end not different. In conclusion: This schedule of sequential MTX/FU seems to be marginally more effective and less toxic than FU alone in inducing remissions in CRC. However, the results of this trial do not suggest a survival benefit for pts receiving MTX/FU. It has already been demonstrated in clinical trials that sequential use of methotrexate (MTX) and 5-Floorouracil (5-FU) may result f~ synergistic tumor cell kill. Recent studies have shown an increasing overall response rate in colon cancer patients with the application of a high-dose of NTX/5-FU in the sequence, compared to the commonly accepted response rate of 15%-2o% with 5-FU treatment alone. In vitro data suggested a superior synergistic effect with longer time intervals for the sequence MTX/5-FU. Regarding the quite substantial toxicity rate with high-dose MTX/5-FU it was necessary to investigate the mffeets of a modified combination with prolonged time intervals and the application of low domes. 24 patients with a median age of 64 years (range 46-76 years) entered the study so far. 6 were pretreeted by radiation, 2 with 5-FN monctherapy. Of the 2o currently evsluable patients 11 had liver metastases: 7 had lung metastases, 5 had lymphnode metastases and 11 abdominal or pelvic masses. The treatment coesisted of MTX 5o mg/m z i.v. bohs injection, fo110wed by MTX 5o mg/m 2 as a 24 hour infusion and here after 6co mg/m a 5-FU as a 6 hour infusion. Leucovorin rescue 22~5 mg (1,5 tablets) was given to al1 patients every 6 hours for eight doses after finishing 5-FU. The first two treatment cycles were repeated every two weeks, then followed by three weeks intervals until progression. A minimum of three treatment cycles was required for evaluation of response using stenderd criteria. Of the 20 currently evaluable patients 4 (20%) achieved a partial response (PR) and 9 (#5%), had stable disease CNC). 7 (35%) showed a progressive disease. Median duration of response (PR and ND) was lo,5 months. Median survial of all patients was 9,0 months so far, but only 4,3 months for patients with progressive disease. No toxicity was observed in the patients, especially no stomabitis, no hairless, no vomiting. There was snty a mild nausea in lo% cf the patients. Significant myelesuppression was not regarded. This data from an ongoing study is promising, updated resulbs will be presented.
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